Mobile website
Clinical Research
Lentinan promotes maturation and function of dendritic cells of acute myeloid leukemia patients
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Objective: To study the effects of lentinan (LNT) on maturation and function of dendritic cells (DCs) of acute myeloid leukemia (AML) patients, so as to explore new ways for leukemia immunotherapy. Methods: Bone marrow mononuclear cells (BMCs) were isolated from AML complete remission (AML-CR) patients, and were induced to differentiate into DCs by GM-CSF and IL-4 for 7 d. DCs were then divided into 3 groups: LPS positive control group, LNT group, and control group. After 48 h, the morphology of DCs was observed by Wright-Giemsa staining in different groups; CD80, CD83, CD86, CD1α, and HLA-DR expressions on DCs were examined by flow cytometry assay; and IL-12 production was determined by ELISA. DCs of AML patients were isolated from human peripheral blood mononuclear cells (PBMC) by magnetic cell sorting (MACS) after LNT therapy, and the concentration of IL-12 in DC supernatants was determined by ELISA. Results: In vitro, LNT-treated DCs showed a typical DC morphology; it concentration-dependently increased the expressions of CD80, CD83, CD86, CD1a and HLA-DR (P＜0.05) and level of IL-12 compared with the control group (P＜0.05). In vivo, IL-12 in the supernatant of DCs of AML patients after LNT therapy was significantly higher than that of untreated patients (P＜0.05). Conclusion: LNT can promote maturation and function of DCs from AML patients in vivo and in vitro, exrting its anti-tumor effect.
Keywords:
Project Supported:
Project supported by the Program of Science and Technology of Gansu Province (No. 0804NKCA115)
Clc Number:
